priors.science/reviews/psoriasis-psoriatic-arthritis

Psoriasis Psoriatic Arthritis

The current evidence on 27 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

27claims tracked
219primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
10 Established · 10 Likely · 4 Uncertain · 2 Doubtful · 1 Refuted  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
IL-17 inhibitors versus ustekinumab PASI 90Pso Il17Established88%9
Risankizumab versus ustekinumab PASI 90Pso Il23Established88%10
Ixekizumab PASI 100 response ratesPso Il17Established87%10
Deucravacitinib versus apremilast PASI 75Pso SMEstablished87%9
Bimekizumab versus secukinumab PASI 90Pso Il17Established86%10
Apremilast PASI 75 efficacyPso SMEstablished86%8
Secukinumab pooled PASI 90 responsePso Il17Established85%10
Upadacitinib ACR50 versus placebo in TNF-inhibitor inadequate respondersPsa JAKEstablished85%6
Tofacitinib ACR20 in psoriatic arthritisPsa JAKEstablished85%8
Tofacitinib major adverse cardiovascular events versus TNF inhibitors in rheumatoid arthritisPsa JsafEstablished85%9
Guselkumab 2-year PASI 90 durabilityPso Il23Likely81%9
Guselkumab ACR20 in biologic-naive psoriatic arthritisPsa PJTLikely81%8
Secukinumab ASAS20 in axial psoriatic arthritisPsa AxlLikely80%7
Risankizumab minimal disease activity in psoriatic arthritisPsa PJTLikely80%4
Bimekizumab ACR50 in biologic-naive psoriatic arthritisPsa PJTLikely80%8
Upadacitinib versus adalimumab in biologic-naive psoriatic arthritisPsa JAKLikely79%8
Secukinumab 5-year ACR20 durabilityPsa PJTLong-standingLikely78%9
Psoriasis as independent cardiovascular risk factorPsa CVDLong-standingLikely77%10
IL-17 inhibitors associated with inflammatory bowel disease incidencePsa CVDLikely71%8
Biologics reduce psoriasis cardiovascular disease riskPsa CVDLikely70%8
Treat-to-target improves psoriatic arthritis outcomesPsa BMKLong-standingUncertain69%8
JAK inhibitors venous thromboembolism riskPsa JsafUncertain61%11
Ixekizumab versus adalimumab ACR50 in psoriatic arthritisPsa PJTUncertain60%9
HLA-Cw6 predicts ustekinumab responsePsa BMKLong-standingUncertain55%8
IL-23p19 inhibitors post-withdrawal durabilityPso Il23Doubtful48%8
IL-17 inhibitors: axial psoriatic arthritis versus axial spondyloarthritis responsePsa AxlDoubtful46%8
JAK cardiovascular risk signal extends to psoriatic arthritisPsa JsafRefuted12%10
Track Psoriasis Psoriatic Arthritis.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.